TY - JOUR
T1 - IVI epoprostenol as salvage therapy in pulmonary arterial hypertension: An Australian perspective
AU - Salamonsen, Matthew R
AU - Keating, Dominic
AU - Whitford, Helen
AU - Bailey, Michael
AU - Miller, T
AU - Manterfield, C
AU - Williams, Trevor John
PY - 2011
Y1 - 2011
N2 - IVI epoprostenol is the only therapy for pulmonary arterial hypertension (PAH) with a randomized controlled trial demonstrating improved survival, when used as first-line monotherapy. In Australia it is used as salvage therapy for those failing treatment with other targeted therapies or presenting in World Health Organization functional class (FC) IV.
AB - IVI epoprostenol is the only therapy for pulmonary arterial hypertension (PAH) with a randomized controlled trial demonstrating improved survival, when used as first-line monotherapy. In Australia it is used as salvage therapy for those failing treatment with other targeted therapies or presenting in World Health Organization functional class (FC) IV.
UR - http://onlinelibrary.wiley.com/doi/10.1111/j.1445-5994.2010.02333.x/pdf
U2 - 10.1111/j.1445-5994.2010.02333.x
DO - 10.1111/j.1445-5994.2010.02333.x
M3 - Article
SN - 1444-0903
VL - 41
SP - 245
EP - 251
JO - Internal Medicine Journal
JF - Internal Medicine Journal
IS - 3
ER -